Biotech RadarJobs updated

COMPANY

Cogent Biosciences, Inc.

HQ: Waltham, MA source · cogentbio.com ↗ · New England

FDA-cleared device company Clinical Phase 3

18 open jobs · last seen Oct 23, 2026 · 17 sources

Cogent Biosciences is a biotechnology company developing solutions to treat genetically driven diseases. From company website Source · Oct 12, 2026

Keywords: Lymphoma Multiple Myeloma HER-2 Protein Overexpression Advanced Systemic Mastocytosis SM With an Associated Hematologic Neoplasm Mast Cell Leukemia Aggressive Systemic Mastocytosis ERBB2 Altered Breast Cancer ERBB2 Gene Amplification HER2 Overexpression Non-Small Cell Lung Cancer HER2 PIK3CA Mutations Endometrial Cancer HR Positive/HER-2 Negative Breast Cancer HER2-low Breast Cancer Indolent Systemic Mastocytoses Aggressive Systemic Mastocytoses Gastrointestinal Stromal Tumors Gastrointestinal Neoplasms Advanced Gastrointestinal Stromal Tumors Indolent Mastocytosis Systemic Mastocytosis Mastocytosis Smoldering Systemic Mastocytosis Bone Marrow Mastocytosis Intrahepatic Cholangiocarcinoma Cholangiocarcinoma FGFR2 Gene Fusion/Rearrangement FGFR2 Gene Amplification FGFR2 Gene Short Variants FGFR3 Gene Fusion/Rearrangement FGFR3 Gene Amplification FGFR3 Gene Short Variants FGFR2 Genetic Alterations

Profile checked Oct 10, 2026

Since the raise (Nov 11, 2025): 18 of 18 open jobs were first seen after it.

18Open jobs$430.0MRaised (2 yrs)14Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Manager, Medical WritingWaltham, Massachusetts, United StatesOct 19, 2026Oct 20, 2026
Senior Clinical Trial AssociateWaltham, Massachusetts, United StatesOct 14, 2026Oct 15, 2026
Associate Director, Accounting OperationsWaltham, Massachusetts, United StatesOct 13, 2026Oct 14, 2026
Associate Director, Training and Contract OperationsWaltham, Massachusetts, United StatesOct 8, 2026Oct 8, 2026
Senior Associate, Pharmacovigilance CoordinatorWaltham, Massachusetts, United StatesOct 5, 2026Oct 8, 2026

See all 18 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (18 open jobs at last check). source ↗
  2. Trial start Phase 1: A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors source ↗
  3. Trial start Phase 1: A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors source ↗
  4. Debt Debt: $200M (not counted as a raise), announced Nov 12, 2025. Source: company release on GlobeNewswire. source ↗
  5. Raise Follow-on offering: $200M (total, as published), announced Nov 11, 2025. Source: SEC filing. source ↗
  6. Raise Follow-on offering: $230M (total, as published), announced Jul 10, 2025. Source: company release on GlobeNewswire. source ↗
  7. Debt Debt financing: $400M (up to, as announced), announced Jun 11, 2025. Source: company release on GlobeNewswire. source ↗
  8. Trial start Phase 1/Phase 2: A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors source ↗
  9. Trial start Phase 2: (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis source ↗
  10. Trial start 3: (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors source ↗
  11. Trial start Phase 2: (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis source ↗
  12. Trial start Phase 1: Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers source ↗
  13. Trial start Phase 1: Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma source ↗
  14. Trial start Phase 1: Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma source ↗
  15. Trial start —: Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product source ↗
  16. Trial start Phase 1: Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma source ↗
  17. Trial start Phase 1/Phase 2: CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 18

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Manager, Medical WritingWaltham, Massachusetts, United StatesOct 19, 2026Oct 20, 2026Not stated
Senior Clinical Trial AssociateWaltham, Massachusetts, United StatesOct 14, 2026Oct 15, 2026Senior
Associate Director, Accounting OperationsWaltham, Massachusetts, United StatesOct 13, 2026Oct 14, 2026Senior
Associate Director, Training and Contract OperationsWaltham, Massachusetts, United StatesOct 8, 2026Oct 8, 2026Senior
Senior Associate, Pharmacovigilance CoordinatorWaltham, Massachusetts, United StatesOct 5, 2026Oct 8, 2026Mid
Manager, Cost AccountingWaltham, Massachusetts, United StatesOct 5, 2026Oct 8, 2026Mid
Senior Director, Global Market AccessWaltham, Massachusetts, United StatesSep 29, 2026Oct 8, 2026Senior
Scientist, DMPK (BioAnalytical and Medical Writing)Boulder, Colorado, United StatesSep 28, 2026Oct 8, 2026Senior
Director, National Payer AccountsWaltham, Massachusetts, United StatesSep 22, 2026Oct 8, 2026Senior
Director, Patient Advocacy & EngagementWaltham, Massachusetts, United StatesSep 21, 2026Oct 8, 2026Senior
Manager, Communications and Investor RelationsWaltham, Massachusetts, United StatesSep 16, 2026Oct 8, 2026Mid
Associate Director, Translational MedicineWaltham, Massachusetts, United StatesSep 14, 2026Oct 8, 2026Senior
Director, Corporate CounselWaltham, Massachusetts, United StatesSep 10, 2026Oct 8, 2026Senior
Contracts SpecialistRemote, United StatesAug 27, 2026Oct 20, 2026Not stated
Associate Director, Patient MarketingWaltham, Massachusetts, United StatesJun 26, 2026Oct 8, 2026Senior
Principal Scientist, Computational ChemistryBoulder, Colorado, United StatesApr 16, 2026Oct 8, 2026Senior
Senior Medical Science Liaison - West Region (Los Angeles, San Diego, Las Vegas, Mountain States {Idaho, Utah, Montana, Wyoming})Remote, United StatesMar 23, 2026Oct 8, 2026Senior
Research Investigator, Computational ChemistryBoulder, Colorado, United StatesFeb 18, 2026Oct 8, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $430.0M · Debt: $600.0M. Last 2 years.

Clinical trials (lead sponsor) 14

RecordTitlePhaseStatusStartPrimary completion
NCT04996875(Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisPhase 2RecruitingNov 9, 2021Sep 19, 2025 (actual)
NCT07361562A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsPhase 1RecruitingDec 30, 20252028-05 (estimated)
NCT07383506A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsPhase 1RecruitingJul 23, 20262029-07 (estimated)
NCT06915766Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic MastocytosisNot listedAvailableNot listedNot listed
NCT06948955Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal TumorsNot listedAvailableNot listedNot listed
NCT05208047(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors3RecruitingApr 14, 2022Sep 30, 2025 (actual)
NCT05186753(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisPhase 2Active, not recruitingJun 27, 2022May 22, 2025 (actual)
NCT06777316A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid TumorsPhase 1/Phase 2Active, not recruitingJan 22, 20252027-03 (estimated)
NCT02401815CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsPhase 1/Phase 2CompletedMar 6, 2015May 11, 2020 (actual)
NCT03189836Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell LymphomaPhase 1TerminatedOct 4, 2017Sep 21, 2020 (actual)
NCT02840110Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell ProductNot listedTerminated2016-10Oct 23, 2020 (actual)
NCT02776813Study of ACTR087 in Subjects With Relapsed or Refractory B-cell LymphomaPhase 1Completed2016-08Feb 12, 2020 (actual)
NCT03680560Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor CancersPhase 1TerminatedMar 13, 2019Mar 12, 2020 (actual)
NCT03266692Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple MyelomaPhase 1TerminatedFeb 22, 2018Oct 1, 2019 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Cogent Biosciences on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback